AlphaQuest LLC Increases Stock Holdings in LifeStance Health Group, Inc. $LFST

Key Points

• AlphaQuest LLC increased its stake in LifeStance Health Group by 144.2% during the first quarter, acquiring an additional 66,621 shares, bringing its total holdings to 112,814 shares valued at approximately $751,000.
• The company reported a quarterly revenue increase of 10.6% year-over-year, totaling $345.31 million, with an EPS of ($0.01), outperforming analyst expectations.
• LifeStance Health Group's stock has a current market cap of $2.16 billion and has seen various institutional investments, significantly influencing its overall ownership, with hedges and institutions holding 85.50% of the company's stock.

AlphaQuest LLC boosted its position in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 144.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 112,814 shares of the company's stock after acquiring an additional 66,621 shares during the quarter. AlphaQuest LLC's holdings in LifeStance Health Group were worth $751,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale purchased a new stake in LifeStance Health Group during the first quarter valued at about $31,000. Xponance Inc. purchased a new stake in LifeStance Health Group during the first quarter valued at about $69,000. Ameriprise Financial Inc. purchased a new stake in LifeStance Health Group during the fourth quarter valued at about $87,000. Kapitalo Investimentos Ltda purchased a new stake in LifeStance Health Group during the first quarter valued at about $87,000. Finally, Forum Financial Management LP purchased a new stake in LifeStance Health Group during the fourth quarter valued at about $110,000. Hedge funds and other institutional investors own 85.50% of the company's stock.

LifeStance Health Group Trading Up 0.9%

Shares of LFST opened at $5.55 on Monday. The stock's 50-day moving average is $4.67 and its two-hundred day moving average is $5.98. The stock has a market cap of $2.16 billion, a PE ratio of -111.00 and a beta of 1.13. LifeStance Health Group, Inc. has a 12 month low of $3.74 and a 12 month high of $8.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.48 and a quick ratio of 1.48.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $345.31 million for the quarter, compared to analysts' expectations of $345.05 million. LifeStance Health Group had a negative return on equity of 1.11% and a negative net margin of 1.23%.The firm's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.06) earnings per share. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Darren M. Black sold 8,407,643 shares of the business's stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total value of $42,626,750.01. Following the transaction, the director owned 33,524,715 shares in the company, valued at approximately $169,970,305.05. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ujjwal Ramtekkar sold 16,000 shares of the business's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $5.94, for a total value of $95,040.00. Following the completion of the transaction, the insider owned 113,435 shares in the company, valued at approximately $673,803.90. This trade represents a 12.36% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,423,643 shares of company stock worth $103,561,790. 6.60% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. BTIG Research assumed coverage on LifeStance Health Group in a research report on Friday, July 25th. They set a "buy" rating and a $8.00 price target for the company. UBS Group boosted their price target on LifeStance Health Group from $8.50 to $9.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded LifeStance Health Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, LifeStance Health Group presently has an average rating of "Moderate Buy" and a consensus target price of $8.50.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

Want to see what other hedge funds are holding LFST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.